These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 29604206

  • 1. From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators.
    Sandner P.
    Biol Chem; 2018 Jun 27; 399(7):679-690. PubMed ID: 29604206
    [Abstract] [Full Text] [Related]

  • 2. Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases.
    Sandner P, Becker-Pelster EM, Stasch JP.
    Nitric Oxide; 2018 Jul 01; 77():88-95. PubMed ID: 29738821
    [Abstract] [Full Text] [Related]

  • 3. Soluble Guanylate Cyclase Stimulators and Activators.
    Sandner P, Zimmer DP, Milne GT, Follmann M, Hobbs A, Stasch JP.
    Handb Exp Pharmacol; 2021 Jul 01; 264():355-394. PubMed ID: 30689085
    [Abstract] [Full Text] [Related]

  • 4. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
    Breitenstein S, Roessig L, Sandner P, Lewis KS.
    Handb Exp Pharmacol; 2017 Jul 01; 243():225-247. PubMed ID: 27900610
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.
    Benza RL, Grünig E, Sandner P, Stasch JP, Simonneau G.
    Eur Respir Rev; 2024 Jan 31; 33(171):. PubMed ID: 38508664
    [Abstract] [Full Text] [Related]

  • 8. The Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-Review.
    Sandner P, Berger P, Zenzmaier C.
    Gerontology; 2017 Jan 31; 63(3):216-227. PubMed ID: 27784018
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
    Triposkiadis F, Xanthopoulos A, Skoularigis J, Starling RC.
    Heart Fail Rev; 2022 Nov 31; 27(6):1991-2003. PubMed ID: 35437713
    [Abstract] [Full Text] [Related]

  • 10. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence.
    Sandner P, Stasch JP.
    Respir Med; 2017 Jan 31; 122 Suppl 1():S1-S9. PubMed ID: 28341058
    [Abstract] [Full Text] [Related]

  • 11. Soluble GC stimulators and activators: Past, present and future.
    Sandner P, Follmann M, Becker-Pelster E, Hahn MG, Meier C, Freitas C, Roessig L, Stasch JP.
    Br J Pharmacol; 2024 Nov 31; 181(21):4130-4151. PubMed ID: 34600441
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
    Koress C, Swan K, Kadowitz P.
    Curr Hypertens Rep; 2016 Apr 31; 18(5):42. PubMed ID: 27118316
    [Abstract] [Full Text] [Related]

  • 14. Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?
    Xiao S, Li Q, Hu L, Yu Z, Yang J, Chang Q, Chen Z, Hu G.
    Mini Rev Med Chem; 2019 Apr 31; 19(18):1544-1557. PubMed ID: 31362687
    [Abstract] [Full Text] [Related]

  • 15. sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension.
    Benza R, Mathai S, Nathan SD.
    Respir Med; 2017 Jan 31; 122 Suppl 1():S28-S34. PubMed ID: 27890470
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
    Armstrong PW, Roessig L, Patel MJ, Anstrom KJ, Butler J, Voors AA, Lam CSP, Ponikowski P, Temple T, Pieske B, Ezekowitz J, Hernandez AF, Koglin J, O'Connor CM.
    JACC Heart Fail; 2018 Feb 31; 6(2):96-104. PubMed ID: 29032136
    [Abstract] [Full Text] [Related]

  • 18. Soluble guanylate cyclase stimulators for the treatment of hypertension: Discovery of MK-2947.
    Brockunier L, Stelmach J, Guo J, Spencer T, Rosauer K, Bansal A, Cai SJ, Chen N, Cummings J, Huang L, Johnson T, Levesque S, Luo L, Maloney K, Metzger J, Mortko C, Ortega K, Pai LY, Pereira A, Salituro G, Shang J, Shepherd C, Sherrie Xu S, Yang Q, Cui J, Roy S, Parmee E, Raghavan S.
    Bioorg Med Chem Lett; 2020 Nov 01; 30(21):127574. PubMed ID: 32980512
    [Abstract] [Full Text] [Related]

  • 19. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
    Pradhan K, Sydykov A, Tian X, Mamazhakypov A, Neupane B, Luitel H, Weissmann N, Seeger W, Grimminger F, Kretschmer A, Stasch JP, Ghofrani HA, Schermuly RT.
    Int J Cardiol; 2016 Aug 01; 216():85-91. PubMed ID: 27140341
    [Abstract] [Full Text] [Related]

  • 20. Hemodynamic Effects of a Soluble Guanylate Cyclase Stimulator, Riociguat, and an Activator, Cinaciguat, During NO-Modulation in Healthy Pigs.
    Næsheim T, How OJ, Myrmel T.
    J Cardiovasc Pharmacol Ther; 2021 Jan 01; 26(1):75-87. PubMed ID: 32662299
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.